The Tangled Web of PID: Malignancies, Autoimmunity, and the Monoclonal Ab Fallout
Tuesday, April 7, 2020
7:00 AM – 9:00 AM
PID is a complex disorder, with a variety of clinical presentations, co-morbidities, and responses to treatment. Immune dysregulation often leads to secondary autoimmunity, malignancy, and inflammation – secondary diagnoses that are frequently recognized as independent events. Novel biologic agents used to treat autoimmune and oncologic conditions can worsen immune deficiency. As a team, healthcare professionals must be able to navigate through these variables to achieve early detection, and good clinical outcomes in patients with PID.
Provide an overview of the intersection of immune dysregulation and autoimmunity
Describe significant complications and comorbidities in PI, as well as the immunosuppressive effects of monoclonal antibodies
Describe major deficiencies in education and collaboration among clinicians